Join the Apretude group to help and get support from people like you.
Apretude News
Despite New Long-Term Options, People Still Prefer Daily PrEP Pill to Prevent HIV
TUESDAY, Oct. 3, 2023 – New ways to deliver drugs that prevent infection with HIV are out there, but many people still prefer the standard daily PrEP pill, a new study shows. “The oral pill is very e...
FDA Approves Apretude (cabotegravir extended-release injectable suspension) for HIV Pre-Exposure Prophylaxis (PrEP)
LONDON--(BUSINESS WIRE) December 20, 2021 --ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi Limited (Shionogi)...
Ask a question
To post your own question to this support group, sign in or create an account.